Marcelo Cruz

1.8k total citations · 1 hit paper
8 papers, 913 citations indexed

About

Marcelo Cruz is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Marcelo Cruz has authored 8 papers receiving a total of 913 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 2 papers in Genetics. Recurrent topics in Marcelo Cruz's work include Cancer Immunotherapy and Biomarkers (3 papers), Lung Cancer Treatments and Mutations (3 papers) and Advanced Breast Cancer Therapies (2 papers). Marcelo Cruz is often cited by papers focused on Cancer Immunotherapy and Biomarkers (3 papers), Lung Cancer Treatments and Mutations (3 papers) and Advanced Breast Cancer Therapies (2 papers). Marcelo Cruz collaborates with scholars based in United States, Brazil and Canada. Marcelo Cruz's co-authors include Young Kwang Chae, Francis J. Giles, Wade T. Iams, Sunandana Chandra, Ayush Arya, Jaehyuk Choi, Ricardo Costa, Benedito A. Carneiro, Sarita Agte and Jonathan F. Anker and has published in prestigious journals such as Scientific Reports, Clinical Pharmacology & Therapeutics and The Oncologist.

In The Last Decade

Marcelo Cruz

8 papers receiving 906 citations

Hit Papers

Current landscape and future of dual anti-CTLA4 and PD-1/... 2018 2026 2020 2023 2018 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)
    2018 321 citations Young Kwang Chae, Ayush Arya et al. Journal for ImmunoTherapy of Cancer profile →

Peers

Marcelo Cruz
Sufei Zheng China
Ashwin Somasundaram United States
Nicholas Theodosakis United States
Davide Pellacani United Kingdom
Amal Qattan Saudi Arabia
Jonathan F. Anker United States
Caiwen Du China
Sofia Genta Canada
Fuchun Guo China
Sufei Zheng China
Marcelo Cruz
Citations per year, relative to Marcelo Cruz Marcelo Cruz (= 1×) peers Sufei Zheng

Countries citing papers authored by Marcelo Cruz

Since Specialization
Citations

This map shows the geographic impact of Marcelo Cruz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marcelo Cruz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marcelo Cruz more than expected).

Fields of papers citing papers by Marcelo Cruz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marcelo Cruz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marcelo Cruz. The network helps show where Marcelo Cruz may publish in the future.

Co-authorship network of co-authors of Marcelo Cruz

This figure shows the co-authorship network connecting the top 25 collaborators of Marcelo Cruz. A scholar is included among the top collaborators of Marcelo Cruz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marcelo Cruz. Marcelo Cruz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Cruz, Marcelo, Romualdo Barroso‐Sousa, Marina Sahade, et al.. (2023). Real-world treatment outcomes in HR+ HER2- metastatic breast cancer patients treated with CDK4/6 inhibitors: Results from a reference center in Brazil. Cancer Treatment and Research Communications. 35. 100683–100683. 11 indexed citations
2.
Chae, Young Kwang, Andrew A. Davis, Sarita Agte, et al.. (2019). Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer. The Oncologist. 24(6). 820–828. 76 indexed citations
3.
Chae, Young Kwang, Ayush Arya, Wade T. Iams, et al.. (2018). Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). Journal for ImmunoTherapy of Cancer. 6(1). 39–39. 321 indexed citations breakdown →
4.
Chae, Young Kwang, Jonathan F. Anker, Sarita Agte, et al.. (2018). Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC). Scientific Reports. 8(1). 2918–2918. 198 indexed citations
5.
Chae, Young Kwang, Jonathan F. Anker, Andrew A. Davis, et al.. (2018). Overexpression of adhesion molecules and barrier molecules is associated with differential infiltration of immune cells in non-small cell lung cancer. Scientific Reports. 8(1). 1023–1023. 33 indexed citations
6.
Chuzi, Sarah, Fábio Távora, Marcelo Cruz, et al.. (2017). Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. Cancer Management and Research. Volume 9. 207–213. 131 indexed citations
7.
Costa, Ricardo, Ami N. Shah, Cesar A. Santa‐Maria, et al.. (2017). Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development. Cancer Treatment Reviews. 53. 111–119. 139 indexed citations
8.
Cruz, Marcelo, Tomás Reinert, & Massimo Cristofanilli. (2017). Emerging Innovative Therapeutic Approaches Leveraging Cyclin‐Dependent Kinase Inhibitors to Treat Advanced Breast Cancer. Clinical Pharmacology & Therapeutics. 103(6). 1009–1019. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sufei Zheng Breakdown of academic impact, for papers by Ashwin Somasundaram Breakdown of academic impact, for papers by Nicholas Theodosakis Breakdown of academic impact, for papers by Davide Pellacani Breakdown of academic impact, for papers by Amal Qattan Breakdown of academic impact, for papers by Jonathan F. Anker Breakdown of academic impact, for papers by Caiwen Du Breakdown of academic impact, for papers by Sofia Genta Breakdown of academic impact, for papers by Fuchun Guo
Rankless by CCL
2026